NCT05244304 - Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions

Stargardt Disease 1

Interventions

DRUG

Tinlarebant

Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.

DRUG

Placebo

Not active drug

Trial Locations (19)

Belite Study Site, Minneapolis

Belite Study Site, Salt Lake City

Belite Study Site, Palo Alto

Belite Study Site, Westmead

Belite Study Site, East Melbourne

Belite Study Site, South Brisbane

Belite Study Site, Ghent

Belite Study Site, Beijing

Belite Study Site, Shanghai

Belite Study Site, Paris

Belite Study Site, Bonn

Belite Study Site, Tübingen

Belite Study Site, Kowloon

Belite Study Site, Nijmegen

Belite Study Site, Basel

Belite Study Site, Taipei

Belite Study Site, Taoyuan

Belite Study Site, London

Belite Study Site, Southampton